ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at JPMorgan Chase & Co.

Equities research analysts at JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note issued on Wednesday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 38.44% from the stock’s previous close.

ANIP has been the topic of several other research reports. Guggenheim boosted their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Up 4.4 %

NASDAQ ANIP opened at $61.40 on Wednesday. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -111.64 and a beta of 0.62. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The business has a 50 day moving average price of $57.86 and a 200-day moving average price of $58.07. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,300 shares of company stock valued at $584,869. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the business. US Bancorp DE lifted its stake in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV raised its position in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $166,000. Finally, HighTower Advisors LLC acquired a new position in shares of ANI Pharmaceuticals in the third quarter worth $222,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.